EA201891469A1 - Агонист длительного действия glp-1r как терапия для лечения неврологических и нейродегенеративных патологических состояний - Google Patents

Агонист длительного действия glp-1r как терапия для лечения неврологических и нейродегенеративных патологических состояний

Info

Publication number
EA201891469A1
EA201891469A1 EA201891469A EA201891469A EA201891469A1 EA 201891469 A1 EA201891469 A1 EA 201891469A1 EA 201891469 A EA201891469 A EA 201891469A EA 201891469 A EA201891469 A EA 201891469A EA 201891469 A1 EA201891469 A1 EA 201891469A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
glp
long
neurological
pathological states
Prior art date
Application number
EA201891469A
Other languages
English (en)
Inventor
Сеулки Ли
Тед М. Досон
Нан Сеок Ко
Вейлина Л. Досон
Сеунг Пил Юн
Магдалена Скалли
Original Assignee
Дзе Джонс Хопкинс Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Джонс Хопкинс Юниверсити filed Critical Дзе Джонс Хопкинс Юниверсити
Publication of EA201891469A1 publication Critical patent/EA201891469A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к композициям и способам лечения нейродегенеративных состояний с применением агонистов GLP-1r. В некоторых вариантах осуществления изобретения агонисты длительного действия GLP-1r оказывают нейропротекторное и изменяющее течение заболевания действие на центральную нервную систему.
EA201891469A 2015-12-23 2016-12-22 Агонист длительного действия glp-1r как терапия для лечения неврологических и нейродегенеративных патологических состояний EA201891469A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562387319P 2015-12-23 2015-12-23
PCT/US2016/068378 WO2017112889A1 (en) 2015-12-23 2016-12-22 Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions

Publications (1)

Publication Number Publication Date
EA201891469A1 true EA201891469A1 (ru) 2018-12-28

Family

ID=59091242

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891469A EA201891469A1 (ru) 2015-12-23 2016-12-22 Агонист длительного действия glp-1r как терапия для лечения неврологических и нейродегенеративных патологических состояний

Country Status (13)

Country Link
US (2) US11123405B2 (ru)
EP (1) EP3393496B1 (ru)
JP (2) JP7026044B2 (ru)
KR (1) KR102508651B1 (ru)
CN (1) CN108697768B (ru)
AU (1) AU2016379403B2 (ru)
CA (1) CA3009506A1 (ru)
DK (1) DK3393496T5 (ru)
EA (1) EA201891469A1 (ru)
ES (1) ES2968038T3 (ru)
LT (1) LT3393496T (ru)
PL (1) PL3393496T3 (ru)
WO (1) WO2017112889A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021020885A1 (ko) * 2019-07-29 2021-02-04 주식회사 펩트론 레보도파 유발 이상 운동증의 치료 또는 진행 억제용 약학 조성물
CN114206374A (zh) * 2019-07-29 2022-03-18 佩特通公司 用于治疗左旋多巴诱导的运动障碍或用于抑制其进展的药物组合物
EP4054620B1 (en) * 2019-11-06 2024-05-29 Novo Nordisk A/S Semaglutide in the treatment of alzheimer's dementia
EP4262873A1 (en) * 2020-12-16 2023-10-25 The Chinese University of Hong Kong A method for reversing aging brain functional decline
CN113350488B (zh) * 2021-07-16 2023-07-14 中国药科大学 口服降糖肽ohp在制备抗神经退行性疾病药物方面的应用
WO2023028554A1 (en) * 2021-08-25 2023-03-02 Neuraly, Inc. Glp-1r agonists for use in a treatment of neurological impairment associated with viral infection
TW202410918A (zh) * 2022-05-27 2024-03-16 韓商Ｄ＆Ｄ製藥科技股份有限公司 用於治療神經病症之組合物及方法

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1137666T5 (da) 1998-12-07 2009-10-05 Univ Tulane GLP-1-analoger
US6872700B1 (en) 1999-01-14 2005-03-29 Amylin Pharmaceuticals, Inc. Methods for glucagon suppression
CA2501421A1 (en) 1999-05-17 2000-11-23 Conjuchem Inc. Long lasting exendin-4
EP1313767A2 (en) 2000-08-24 2003-05-28 Thomas Jefferson University Peptide with effects on cerebral health
US20050222036A1 (en) 2000-08-24 2005-10-06 Thomas Jefferson University Peptide compositions with effects on blood glucose
DE60228972D1 (de) 2001-07-31 2008-10-30 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
AU2014277804B2 (en) 2001-07-31 2016-12-01 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Glp-1 exendin-4 peptide analogs and uses thereof
AU2003273300A1 (en) 2002-09-06 2004-03-29 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
US6969702B2 (en) 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
JP2007524579A (ja) 2003-02-19 2007-08-30 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Ｇｌｐ−１の類似体
ES2315664T3 (es) 2003-06-30 2009-04-01 Domantis Limited Anticuerpos de dominio unico (dab) pegilados.
ES2303132T3 (es) 2003-08-07 2008-08-01 Zymogenetics, Inc. Preparaciones homogeneas de il-29.
PL1729795T3 (pl) 2004-02-09 2016-08-31 Human Genome Sciences Inc Białka fuzyjne albuminy
JP2008516621A (ja) 2004-10-18 2008-05-22 ノボ ノルディスク アクティーゼルスカブ 成長ホルモン結合体
AU2012202972A1 (en) 2005-09-22 2012-06-14 Biocompatibles Uk Ltd GLP-1 fusion peptides, their production and use
DK1767545T3 (da) 2005-09-22 2010-03-15 Biocompatibles Uk Ltd GLP-1 (Glucagon-lignende peptid-1)-fusionspolypeptider med forøget peptidaseresistens
ES2390286T3 (es) 2005-12-16 2012-11-08 Nektar Therapeutics Conjugados poliméricos de GLP-1
AU2013201640A1 (en) 2006-04-14 2013-04-11 Mannkind Corporation Glucagon-like peptide 1(GLP-1) pharmaceutical formulations
ATE444741T1 (de) 2006-05-10 2009-10-15 Biocompatibles Uk Ltd Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung
KR100890989B1 (ko) 2006-06-01 2009-03-31 이강춘 폴리에틸렌글리콜 또는 이의 유도체로 단일 수식된 엑센딘,이의 제조방법 및 이의 용도
EP2057189B1 (en) 2006-08-25 2013-03-06 Novo Nordisk A/S Acylated exendin-4 compounds
CN101195612B (zh) 2006-12-05 2012-08-08 中国科学院上海药物研究所 一类具有取代环丁烷结构的化合物、及其制备方法和医学用途
US8617531B2 (en) 2006-12-14 2013-12-31 Bolder Biotechnology, Inc. Methods of making proteins and peptides containing a single free cysteine
WO2008130066A1 (en) 2007-04-20 2008-10-30 Kang Choon Lee Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
US9353170B2 (en) * 2007-06-08 2016-05-31 Sanofi-Aventis Deutschland Gmbh Long-acting transient polymer conjugates of exendin
WO2010080578A1 (en) 2008-12-18 2010-07-15 Phasebio Pharmaceuticals, Inc. Biologically active proteins activatable by peptidase
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
CN101870728A (zh) 2009-04-23 2010-10-27 派格生物医药(苏州)有限公司 新型Exendin变体及其缀合物
CA2764108A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
WO2011003007A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
CN102596993A (zh) 2009-07-02 2012-07-18 安吉奥开米公司 多聚体肽结合物以及其应用
KR101112578B1 (ko) 2009-07-16 2012-02-16 성균관대학교산학협력단 엑센딘의 비강투여용 약제학적 조성물 및 이의 제조방법
WO2011017554A2 (en) 2009-08-07 2011-02-10 Mannkind Corporation Val (8) glp-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
EP2505941B1 (en) 2009-11-25 2019-05-15 Daikin Industries, Ltd. Refrigeration device for container
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
CA2797089A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
ES2661228T3 (es) 2010-05-13 2018-03-28 Indiana University Research And Technology Corporation Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
PL2571510T3 (pl) 2010-05-21 2019-03-29 Xl-Protein Gmbh Biosyntetyczne polipeptydy prolinowo/alaninowe o strukturze kłębka statystycznego i ich zastosowania
MX2013000250A (es) 2010-07-02 2013-10-28 Angiochem Inc Polipeptidos cortos y que contienen d-aminoacido para conjugados terapeuticos y usos de los mismos.
US20130137645A1 (en) * 2010-07-19 2013-05-30 Mary S. Rosendahl Modified peptides and proteins
BR112013007442A2 (pt) 2010-09-28 2019-09-24 Amylin Pharmaceuticals Llc polipeptídeos construídos tendo duração de ação realçada
CN102786590A (zh) * 2011-05-19 2012-11-21 江苏豪森药业股份有限公司 分枝型peg修饰的glp-1类似物及其可药用盐
BR112013032717A2 (pt) 2011-06-22 2017-01-24 Univ Indiana Res & Tech Corp coagonistas do receptor de glucagon/glp-1
DK2723367T3 (en) 2011-06-22 2017-07-17 Univ Indiana Res & Tech Corp Glucagon / GLP-1 receptor-CO-AGONISTS
JP2014520159A (ja) 2011-06-24 2014-08-21 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー Ｇｌｐ−１受容体アゴニストの徐放性製剤による糖尿病の治療方法
KR101357117B1 (ko) * 2011-06-28 2014-02-06 비앤엘델리팜 주식회사 폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
EP2729493B1 (en) 2011-07-04 2020-06-10 IP2IPO Innovations Limited Novel compounds and their effects on feeding behaviour
EP2729481B1 (en) 2011-07-08 2018-10-17 Amylin Pharmaceuticals, LLC Engineered polypeptides having enhanced duration of action with reduced immunogenicity
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
EP2578599A1 (en) 2011-10-07 2013-04-10 LanthioPep B.V. Cyclic analogs of GLP-1 and GLP-1 related peptides
WO2013074910A1 (en) 2011-11-17 2013-05-23 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
WO2013119650A1 (en) 2012-02-06 2013-08-15 Board Of Regents Of The University Of Nebraska Delivery of biotherapeutics to the brain
EP2630965A1 (en) 2012-02-24 2013-08-28 Curatis Pharma GmbH A polypeptide for the protection from neurodegeneration in patients with amyotrophic lateral sclerosis (ALS)
WO2013148966A1 (en) 2012-03-28 2013-10-03 Amylin Pharmaceuticals, Llc Transmucosal delivery of engineered polypeptides
WO2013148871A1 (en) 2012-03-28 2013-10-03 Amylin Pharmaceuticals, Llc Engineered polypeptides
CA2872315A1 (en) 2012-05-03 2013-11-07 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
TWI644920B (zh) 2012-06-21 2018-12-21 美商印第安納大學科技研究公司 展現ｇｉｐ受體活性之胰高血糖素類似物
CA2882958A1 (en) 2012-08-29 2014-03-06 Mannkind Corporation Method and composition for treating hyperglycemia
WO2014041375A1 (en) 2012-09-17 2014-03-20 Imperial Innovations Limited Peptide analogues of glucagon and glp1
EP2928562A4 (en) * 2012-12-06 2016-06-22 Stealth Peptides Int Inc PEPTIDE THERAPEUTIC PRODUCTS AND METHODS OF USE
AR094180A1 (es) 2012-12-21 2015-07-15 Sanofi Sa Derivados de exendina-4
EP2943213A4 (en) 2013-01-08 2016-08-17 Jerome Schentag ACTIVATION OF THE ENDOGENOUS HORMONE PATHWAY OF ILLEAL BRAKE FOR THE REGENERATION OF AN ORGAN AND ASSOCIATED COMPOSITIONS, METHODS OF TREATMENT, DIAGNOSTICS, AND REGULATORY SYSTEMS
US9707273B2 (en) 2013-03-01 2017-07-18 Fundació Hospital Universitari Vall D'hebron—Institut De Recerca Peptides for use in the topical treatment of retinal neurodegenerative diseases, in particular in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role
US9693968B2 (en) 2013-03-14 2017-07-04 Jerome J. Schentag Cholestosome vesicles for incorporation of molecules into chylomicrons
WO2014179983A1 (zh) 2013-05-10 2014-11-13 北京华金瑞清生物医药技术有限公司 一种改造非抗体类蛋白产生结合分子的方法、所产生的产品和一种长效glp-1受体激动剂
CN105377306B (zh) 2013-06-20 2020-03-17 诺和诺德股份有限公司 Glp-1衍生物和其用途
JP6139712B2 (ja) 2013-07-04 2017-05-31 ノヴォ ノルディスク アー／エス Ｇｌｐ−１様ペプチドの誘導体及びその使用
US10266577B2 (en) 2013-08-15 2019-04-23 Novo Nordisk A/S GLP-1 derivatives, and uses thereof
ES2927607T3 (es) 2013-09-13 2022-11-08 Scripps Research Inst Agentes terapéuticos modificados y composiciones de los mismos
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
TW201609800A (zh) 2013-12-13 2016-03-16 賽諾菲公司 做為雙重ｇｌｐ－１／升糖素受體促效劑之艾塞那肽－４胜肽類似物
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
EP3080151A1 (en) 2013-12-13 2016-10-19 Sanofi Exendin-4 peptide analogues
EP4212180A1 (en) 2013-12-18 2023-07-19 The Scripps Research Institute Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
GB201404002D0 (en) 2014-03-06 2014-04-23 Imp Innovations Ltd Novel compounds
CN106661128A (zh) 2014-06-06 2017-05-10 加州生物医学研究所 构建氨基末端免疫球蛋白融合蛋白的方法及其组合物
GB2528436A (en) 2014-07-15 2016-01-27 Lancaster Univ Business Entpr Ltd Treatment of neurological diseases
JP2017528431A (ja) 2014-07-17 2017-09-28 ジェローム シェンターク， 器官再生のための内因性回腸ブレーキホルモン経路の活性化、並びに関連する組成物、治療方法、診断、及び制御システム
US11572398B2 (en) 2014-11-27 2023-02-07 Novo Nordisk A/S GLP-1 derivatives and uses thereof
EP3233898A1 (en) 2014-12-17 2017-10-25 Novo Nordisk A/S Glp-1 derivatives and uses thereof
US10730911B2 (en) 2015-04-08 2020-08-04 Universitat Zurich Backbone-cyclized peptidomimetics with GLP-1R modulating activity
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
CN107921098A (zh) 2015-06-17 2018-04-17 加州生物医学研究所 修饰的治疗剂及其组合物
CN106110325A (zh) 2016-06-08 2016-11-16 上海朗安生物技术有限公司 一种新型 glp‑1 受体激动剂的制备方法及其在神经退行性疾病治疗领域的应用
US20210353710A1 (en) * 2020-03-05 2021-11-18 The Johns Hopkins University Glp-1r agonist and methods of treatment

Also Published As

Publication number Publication date
JP2020059735A (ja) 2020-04-16
CA3009506A1 (en) 2017-06-29
KR20180096733A (ko) 2018-08-29
DK3393496T3 (en) 2023-11-13
US11123405B2 (en) 2021-09-21
WO2017112889A1 (en) 2017-06-29
JP7026044B2 (ja) 2022-02-25
EP3393496B1 (en) 2023-10-11
DK3393496T5 (da) 2024-09-16
PL3393496T3 (pl) 2024-04-22
JP2019500369A (ja) 2019-01-10
EP3393496A4 (en) 2019-07-31
CN108697768A (zh) 2018-10-23
EP3393496A1 (en) 2018-10-31
ES2968038T3 (es) 2024-05-06
US20220111010A1 (en) 2022-04-14
AU2016379403A1 (en) 2018-07-19
LT3393496T (lt) 2023-12-11
CN108697768B (zh) 2022-07-22
KR102508651B1 (ko) 2023-03-13
US20180369340A1 (en) 2018-12-27
AU2016379403B2 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
EA201891469A1 (ru) Агонист длительного действия glp-1r как терапия для лечения неврологических и нейродегенеративных патологических состояний
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
EA201891251A1 (ru) Бициклические ингибиторы pad4
EA201890908A1 (ru) Композиции и способы для лечения мышечной дистрофии дюшенна и сходных нарушений
EA201890058A1 (ru) Производное глюкагона и композиция, содержащая длительно действующий конъюгат этого производного
MX2018005132A (es) Agonistas del receptor de glucagon.
EA201890204A1 (ru) Антибактериальные соединения
MX2018005829A (es) Composiciones para tratar el cabello.
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
NZ755605A (en) Compositions for modulating tau expression
EA201690629A1 (ru) Соединения, которые представляют собой тройные агонисты, глюкагона, glp-1 и gip
EA201891539A1 (ru) Соединения, ингибирующие металлоферменты
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
ECSP17038999A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
EA201891376A1 (ru) Бензотиофеновые селективные блокаторы эстрогеновых рецепторов
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
EA201890810A1 (ru) Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
EA201890747A1 (ru) Способы лечения воспалительных заболеваний